Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene clues in ovarian cells could boost IVF success

NCT ID NCT04710264

Knowledge-focused Sponsor: Fertiga, Belgium Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at genes in cumulus cells (cells that surround eggs) from 137 women undergoing IVF. The goal was to find genetic markers that predict which embryos are most likely to lead to a pregnancy. Researchers compared two different hormone treatments to see if gene patterns differ. This is an observational study, so it does not test a new treatment but aims to improve embryo selection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a genetic test that helps doctors choose the best embryo for IVF, improving pregnancy chances.
What could go wrong
This is an observational study, not a treatment trial. The findings may not lead to a reliable test, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

137 people

The number who actually took part.

Started

Feb 2021

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients for this study must be between 22-38 years of age, have a good ovarian reserve and response, and need to be naïve to IVF/ ICSI or have only one prior ICSI cycle. Only patients with 7-18 follicles at the end of ovarian stimulation will be allowed to enter the study on the day of decision of hCG injection (or the day before). Patients with fewer than 7 oocytes will be excluded from the study.

Ages

22 to 38 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients are between 22-38 years old * BMI between 17-33 * provide written informed consent * Patients undergoing a first or second ICSI treatment cycle. * Patients will be treated by ICSI (intracytoplasmic sperm injection) * Patients agree that the oocytes will be denuded for cumulus testing and agree to the single blastocyst transfer. * Patients must be predicted good ovarian responders (AMH 1-4,7 ng/ml) with 7-18 follicles of minimum 10-11 mm on trigger day (oocyte retrieval minus 2 days (OR -2)) by ultrasound following ovarian stimulation with r-hFSH or r-hFSH with r-hLH in a Gonadotropin-releasing hormone (GnRH) antagonist protocol (starting dose recombinant Follicle Stimulating Hormone (rFSH) between 150-225 IU) * HCG trigger after stimulation (r-hCG) Exclusion Criteria: * Women with less than 7 or more than 18 follicles at Day -2 or -3 measured by ultrasound * Women with history of poor oocyte maturation or known maturation defect * Irregular menstrual cycle (\< 24 or \> 35 days) * BMI \< 17 or \> 33 * Smoking \> 10 cigarettes per day. * Known low ovarian response based on Bologna criteria * Combined use of urinary and recombinant gonadotropins in the current cycle * Patients with severe endometriosis ≥ III (AFS classification) * Polycystic ovary syndrome (PCOS), defined by revised criteria American Society for Reproductive Medicine (ASRM) European Society of Human Reproduction and Embryology (ESHRE) 2018 * Patient included in any other study * Patient scheduled for preimplantation genetic testing (PGT) * Testicular sperm extraction (TESE) or extreme oligo-astheno-teratozoospermia (OAT) with sperm count below 100.000/ml.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infertility are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertility

Contacts and locations

Locations

  • Universitair Ziekenhuis Brussel

    Jette, 1090, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.